Schedule or dosage? The need to perfect intermittent regimens for tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 10, 2006, Pages 1067-1068

  Saltini, Cesare ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

COMORBIDITY; COST OF ILLNESS; DRUG EFFICACY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TREATMENT PLANNING; TUBERCULOSIS; UNITED STATES; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; HUMANS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 33750873908     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200608-1194ED     Document Type: Editorial

References (16)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2006. Geneva, Switzerland: World Health Organization; 2006. Publication No. WHO/HTM/TB/2006.362.
2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021.
3. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-526.
4. Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L, Iemoli E. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 1998;12:1095-1102.
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization; 2006. Publication No. WHO/HTM/TB/2006.361.
6. International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis regimens of chemotherapy: recommendations from the committee on treatment. Bull Int Union Tuberc Lung Dis 1988;6:60-64.
7. Bocchino M, Greco S, Rosati Y, Mattioli G, Marruchella A, De Mori P, Bibbolino C, Girardi E, Squarcione S, Saltini C. Cost determinants of tuberculosis management in a low-prevalence country. Int J Tuberc Lung Dis 2006;10:146-152.
8. World Health Organization. Treatment of tuberculosis: guidelines for national programs. Geneva, Switzerland: World Health Organization; 1997. Publication No. WHO/TB/97.220.
9. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981;1:171-174.
10. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev 2001;4:CD000970.
11. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:1153-1158.
12. Hawken M, Nunn P, Gathua S, Brindle R, Godfrey-Faussett P, Githui W, Odhiambo J, Batchelor B, Gilks C, Morris J. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993;342:332-337.
13. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364:1244-1251.
14. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, et al.; Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006;173:350-356.
15. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40:1481-1491.
16. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005;41:461-469.